Press Release

MEMO FROM DR. LEN SANDS OF THE SAN DIEGO
IMMUNOLOGICAL CENTER

A Comprehensive Perspective of CMO May 1999 as an Adaptagenic
Immunomodulator by Dr. Len Sands

CMO is the world's first and only true adaptagenic immunomodulator.

Only CMO has corrective and restorative immunomodulatory properties for
auto immune disease. Other so-called "immunomodulators" do not. They
function primarily as immunosuprressants or immunostimulants. They are
capable of only one principal action, either suppressing or stimulating immune
function. CMO, on the other hand, permanently corrects autoimmune
programs within the memory T-cells themselves rather than just temporarily
suppressing or stimulating immune system activities. That is why a single
CMO therapy program usually lasts forever without any need to repeat the
therapy or use any additional medication of any kind.

CMO is not an immunosuppressant, nor an immuostimulant. Nor is it a
pharmaceutical. It is a naturally derived substance that has received the highest
safety level by certified independent laboratory testing.

Some practitioners have theorized that, in the case of arthritis for example,
CMO merely acts upon pain receptors at the arthritis site. If that were so,
CMO's effects would not be permanent. Furthermore, that theory cannot
explain:

how CMO lowers blood sedimentation rates in Lupus patients,
or how it reverses lung inflammation in emphysema,
or how it lowers the need for insulin in diabetics
or how it reverses prostate inflammation
or how it relieves certain symptoms of multiple sclerosis,
or how it corrects Crohn's disease,
or how it reverses fibromyalia
or how it lowers high blood pressure yet elevates low blood pressure
or how it benefits virtually any ailment with auto immune components

Obviously, CMO is a general remedial immunomodulator that acts upon the
memory T-cells which control the autoimmune processes within our bodies.
Those who speculate otherwise have misunderstood the biophysiological
actions of CMO within the body.

It is also important to understand that CMO acts only upon the memory
T-cells and does not inhibit the activities of any of the several other types of
T-cells that are responsible for combating infective microorganisms or invading
substances.

Unlike the immunosuppressants commonly used to try to temporarily control the
symptoms of autoimmune diseases, CMO does not leave the body
vulnerable to attack by disease-causing agents. Nor does it inhibit the body's
resistance to tumor formation, as do the dangerous new tumor necrosis factor
(TNF) suppressants of some new arthritis drugs.

Copyright 1999 Dr. L. Sands. All rights reserved.


NO DOUBLE BLIND, PLACEBO CONTROLLED TESTS HAVE BEEN DONE ON HUMANS. ALL BENEFITS FROM Original CMO ON PEOPLE WITH FIBROMYALGIA IS ANECDOTAL.

The CMO Fibro package is available at
www.cmorelief.com

Home | Impostors | Feedback